New PNH drug LP-005 passes first safety check in healthy volunteers
NCT ID NCT06294301
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 17 times
Summary
This early-stage study tested the safety and tolerability of a new drug called LP-005 in 68 healthy adults aged 18 to 50. The drug is being developed for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Participants received either a single or multiple doses to see how the body processes the drug and if any side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.